Gene Sequencing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The gene sequencing market size is projected to be USD 6.94 billion in 2025, USD 7.82 billion in 2026, and reach USD 14.17 billion by 2031, growing at a CAGR of 12.64% from 2026 to 2031. This report is Segmented by Technology Type (Next-Generation Sequencing, Sanger Sequencing, and More), Product (Sequencing Instruments, Consumables, and Others), Application (Clinical Diagnostics, and More), End User (Hospitals and Diagnostic Laboratories, and More), and Geography (North America, Europe, Asia-Pacific, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Gene Sequencing Market Trends and Insights

Rising Clinical Adoption of Precision Oncology Panels

Clinical oncology remains the strongest demand engine in the gene sequencing market because comprehensive genomic profiling still has room to penetrate a larger eligible patient pool. The US Centers for Medicare & Medicaid Services continues to provide a reimbursement foundation through NCD 90.2 for advanced cancer patients when next-generation sequencing tests carry FDA approval or clearance as companion diagnostics, and that framework is supporting lab investment in validated platforms. The same gene sequencing market is also gaining support from minimal residual disease and molecular residual disease monitoring, where repeated liquid biopsy testing raises the need for high-sensitivity sequencing instead of legacy PCR workflows. That pattern matters because serial testing creates recurring run volumes rather than one-time diagnostic events, which improves utilization for installed instruments. As more targeted therapies require companion diagnostic support, labs without sequencing capability face a weaker competitive position and a harder path to clinical relevance. This is why the gene sequencing market is not only adding test volume, but it is also becoming more embedded in routine treatment-selection pathways.

Falling Per-Base Sequencing Cost and Higher Throughput

The gene sequencing market is benefiting from a faster cost reset as vendors push throughput gains and lower consumables expenses into commercial workflows. PacBio stated in 2026 that its SPRQ-Nx chemistry, together with SMRT cell reuse, enabled HiFi whole-genome sequencing below USD 300 per sample at scale, which moves long-read sequencing closer to budget levels that broader clinical programs can support. Illumina also launched TruPath Genome in February 2026 at USD 395 per sample for consumables plus analysis on existing NovaSeq X infrastructure, which lowers adoption friction because labs do not need to buy a new instrument to access long-range genomic insight. These moves change buying behavior because lower per-sample costs make test volume and workflow fit more important than headline instrument pricing alone. In the gene sequencing market, that shift favors vendors that can hold customers through software, assay design, data interpretation, and quality assurance rather than through reagent pricing only. It also means that platforms with weaker workflow integration may struggle even when their raw sequencing performance is competitive.

High Capital Intensity of Sequencers and Automation

The gene sequencing market still carries one of the heavier capital barriers in diagnostics because high-throughput instruments require large upfront spending and multi-year depreciation before labs can earn healthy margins. High-end systems remain difficult for many community hospitals and regional laboratories to justify without leasing options, shared-service models, or volume commitments. The problem extends beyond the sequencer because clinical-scale operation also needs liquid handling, automated library preparation, and secure informatics infrastructure. Falling reagent costs help, but they do not remove the burden of underused instruments in labs that lack consistent sample flow. This creates a two-tier structure in the gene sequencing market, where well-funded academic centers and reference labs can spread costs over larger volumes while smaller providers struggle to build a viable business case. It also delays wider geographic expansion because many low- and middle-income markets need lower-risk deployment models before local sequencing capacity can scale.

Other drivers and restraints analyzed in the detailed report include:

• Population-Scale Genomics and Biobank Expansion
• Shift Toward Long-Read Sequencing in Structural Variant Discovery
• Data Governance, Privacy, and Cross-Border Genomic Data Limits

Segment Analysis

Next-generation sequencing held 68.57% of the gene sequencing market share in 2025, reflecting years of clinical validation, a deep reagent ecosystem, and a large installed base across academic centers and reference laboratories. That leadership remains hard to displace because customers already have validated workflows, trained teams, and procurement relationships tied to short-read platforms. Sanger sequencing still retains a smaller but durable role in confirmation work, especially when labs need lower-throughput validation without running a full next-generation workflow. This keeps a practical place for older methods even as high-volume sequencing moves toward broader panel, exome, and genome use. The gene sequencing market therefore remains anchored by next-generation sequencing today, but that anchor is becoming less exclusive as long-read systems improve on cost and workflow readiness.

Third-generation sequencing is projected to expand at 12.96% CAGR through 2031, making it the fastest-growing technology category in the gene sequencing market. Demand is rising because structural variant detection, phased genome assembly, methylation analysis, and repeat region resolution are all areas where native long reads add value that short-read methods do not fully match. PacBio stated in 2026 that SPRQ-Nx chemistry allows SMRT cell reuse and supports HiFi whole-genome sequencing below USD 300 per sample at scale, which marks an important affordability threshold for broader program adoption. Illumina’s TruPath Genome also shows that short-read incumbents are trying to keep customers by adding long-range insight on existing hardware rather than surrendering that demand to long-read specialists. By 2031, the technology mix in the gene sequencing market is likely to look less one-sided because labs that need difficult variant resolution will have stronger reasons to adopt or add long-read capability.

Consumables accounted for 52.79% of revenue in 2025, which shows how strongly the gene sequencing market depends on recurring purchases rather than one-time capital sales. Flow cells, reagent kits, and library preparation products are bought on every run, so revenue rises with throughput even when instrument placement slows. This pattern gives established vendors a more stable base because each active instrument becomes a repeat source of consumable demand over several years. It also means customer retention matters as much as new customer acquisition, since losing a platform account affects a recurring revenue stream rather than a single product sale. The gene sequencing industry, therefore, relies on installed-base durability, workflow convenience, and assay consistency to protect its largest product pool.

The gene sequencing market size for sequencing instruments is projected to expand at 13.52% CAGR from 2026 to 2031 as labs upgrade older benchtop systems and add higher-throughput platforms for clinical panels, exomes, and whole genomes. Instrument demand is also supported by the need to move testing closer to decentralized clinical settings, where turnaround time and sample control matter more. Even so, the long-run revenue mix is likely to lean further toward consumables because replacement cycles stretch across several years while run volumes can rise more continuously. This helps explain why vendors are pairing new instrument launches with chemistry, software, and automation changes that lift the value of each installed system rather than relying on placements alone. In the gene sequencing market, instruments open the door, but consumables still determine the durability of the revenue model.

Complete Report Scope:

• By Technology Type
  • Next-Generation Sequencing (NGS)
  • Sanger Sequencing
  • Third-Generation Sequencing
  • Others
• By Product
  • Sequencing Instruments
  • Consumables
  • Others
• By Application
  • Clinical Diagnostics
  • Research and Academic Applications
  • Drug Discovery and Development
  • Population Genomics
  • Others
• By End User
  • Hospitals and Diagnostic Laboratories
  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.37% of gene sequencing market share in 2025, which kept it as the largest regional contributor. The United States continues to benefit from a stronger reimbursement base in oncology because CMS NCD 90.2 supports approved or cleared next-generation sequencing companion diagnostics for advanced cancer patients. That coverage structure supports investment in validated clinical sequencing workflows across cancer centers, hospital labs, and reference networks. Florida’s Medicaid program also activated reimbursement in 2025 for rapid whole-genome sequencing at USD 2,716.9 per test, which shows that clinical whole-genome sequencing is extending into neonatal and pediatric rare disease use cases at the state level. Canada and Mexico remain smaller contributors within the region, but lower cost thresholds and wider rare disease access are helping broaden the gene sequencing market beyond the United States.

Europe remained the second-largest regional block in 2025, with Germany, the United Kingdom, and France contributing most of the regional revenue. The United Kingdom has a working operational base through Genomics England and the NHS Genomic Medicine Service, which gives whole-genome sequencing a clearer pathway in rare disease and cancer care. Germany’s statutory health insurance system has also deepened support for comprehensive genomic profiling in oncology, which is helping sequencing move further beyond academic centers. The region’s growth is still moderated by GDPR-driven data residency and transfer requirements, which raise infrastructure costs and make it harder for smaller labs to match the operating resilience of large platform vendors.

Asia-Pacific is projected to expand at 14.53% CAGR through 2031, making it the fastest-growing geography in the gene sequencing market. China’s competitive environment is being reshaped by aggressive domestic platform positioning and stricter control over foreign genomic data participation. MGI Tech announced in March 2026 the acquisition of STOmics and CycloneSEQ, which broadened its coverage across short-read sequencing, long-read nanopore sequencing, and spatial omics under one portfolio. South Korea is also strengthening long-read and reference genome capability, while India’s genome mapping efforts are supporting sustained instrument and consumable demand over multiple years. The Middle East and Africa and South America remain at earlier stages, but genomics infrastructure spending in GCC markets and the expansion of clinical sequencing networks in Brazil are creating identifiable entry points for the gene sequencing market.

List of Companies Covered in this Report:

• 10x Genomics, Inc.
• Agilent Technologies
• Beckton Dickinson
• BGI
• Bio-Rad Laboratories
• Danaher
• Eurofins
• Roche
• Guardant Health, Inc.
• Illumina
• Invitae
• MGI Tech Co., Ltd.
• Myriad Genetics
• Natera, Inc.
• Novogene Co., Ltd.
• Oxford Nanopore Technologies plc
• Pacific Bioscience
• PerkinElmer
• QIAGEN
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support